USV Expands Diabetes Portfolio with Cost-Effective Liralin-EP in India Deeksha Bhandari22 March 2025 1:00 PM ISTUSV Pvt. Ltd., launches the Liralin EP a combination of Linagliptin & Empagliflozin at just Rs 12.90 per tablet for strengthening it's affordable...
Use of Generic DPP4i + SGLT2i FDCs by Indian Physicians - The DiSi Survey Dr. Garima Soni19 Feb 2025 11:28 AM ISTThe Indian phenotype of T2DM patients is associated with clustering of cardiovascular risk factors, increased insulin resistance, and reduced...
Medical Bulletin 07/ August/ 2024 Dr. Nandita Mohan7 Aug 2024 3:00 PM ISTHere are the top medical news for the day:New Study Reveals Link Between Obesity and Increased Risk of Heart FailureA recent study led by Johns...
Study shows SGLT2i or Finerenone Added to RAAS Inhibitors Offers Kidney and Heart Protection for Diabetics with CKD Dr. Nandita Mohan7 Aug 2024 8:00 AM ISTType 2 diabetes (T2D) is the leading cause of end-stage kidney disease (ESKD) globally. The presence of both T2D and CKD poses a major public health...
Add on SGLT2i or finerenone to RAAS inhibitor may provide kidney and CV protection in diabetics with CKD: Study Dr. Shravani Dali5 Aug 2024 9:00 AM ISTAdd on SGLT2i or finerenone to RAAS inhibitor may provide kidney and CV protection in diabetics with CKD suggests BMC nephrology.Given the substantial...
Evergreen Talk Series: How can Safety and Tolerability of Linagliptin and Dapagliflozin benefit diverse T2DM population? MD Brand Connect25 March 2024 4:38 PM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani, an...
EVERGREEN Webinar: Clinical FAQs on T2DM Care, Addressed by Dr V Mohan Dr Jeegar Dattani6 March 2024 12:29 PM ISTThe Evergreen webinar addressed the clinical applicability of Linagliptin and Dapagliflozin in real-world clinical scenarios of type 2 diabetes....
Evergreen Talk Series: Use of SGLT2i and DPP4i combination in T2DM patients with a history of Genitourinary Tract Infections MD Brand Connect1 Feb 2024 10:30 AM ISTPresenting the Evergreen Talk Series featuring Dr. Brij Mohan Makkar, a Senior Diabetologist and Obesity Specialist from Delhi, Dr Sameer I. Dani,...
SGLT2 inhibitors may slow progression of diabetic retinopathy: JAMA Dr. Shravani Dali21 Dec 2023 10:00 PM ISTSGLT2 inhibitors may lower risk of diabetic nephropathy and cut progression of diabetic retinopathy suggests a new study published in the...
ESC 2023 Updates Guideline for Managing Cardiovascular Disease in Diabetes Dr. Prem Aggarwal28 Aug 2023 11:15 AM ISTThe European Society of Cardiology (ESC) released Guidelines for Managing Cardiovascular Disease in Patients with Diabetes, 2023.The guideline,...
SGLT2 inhibitors improve FIB-4 index better than pioglitazone in MAFLD patients Aditi20 March 2023 10:30 AM ISTJapan: A study entitled "Effects of sodium-glucose cotransporter two inhibitors and pioglitazone on FIB-4 index in metabolic associated fatty liver...
Early initiation of SGLT2 inhibitors reduces MACE in Type 2 Diabetes patients at ASCVD risk Aditi29 Nov 2022 12:15 PM ISTChina: An investigation has revealed that initiation of SGLT2 inhibitor early in Type 2 Diabetes (T2D) patients reduces the rates of major adverse...
